Nautilus Biotechnology, Inc.

What they do

Nautilus is developing the Nautilus Voyager platform, an end-to-end system integrating nanofabricated protein arrays, affinity reagents, optics, fluidics, and machine learning to quantify single, intact protein molecules. The company's Iterative Mapping method is designed to provide broad and deep proteome characterization with high reproducibility. As of mid-2026, the platform remains under development, and the company has launched a services-based Early Access program to commercialize specific proteoform assays.

Revenue drivers

• Iterative Mapping Early Access Program — A services-based program launched in Q1 2026, generating initial service revenue in Q2 2026; Tau Proteoforms Assay is the first application.
• Grant revenue — Revenue from a Michael J. Fox Foundation grant supporting alpha-synuclein proteoform assay development, recognized in Q2 2026.
• Future consumable kits — Planned revenue from consumable kits for proteoform assays, including Tau and AKT1, with general availability expected in mid-2027.

Recent performance

In Q2 2026, Nautilus reported its first revenue of $0.2 million, primarily from the Michael J. Fox Foundation grant and Early Access service revenue. Operating expenses were $15.9 million, down 7% from $17.1 million a year earlier. Net loss was $14.5 million, slightly improved from $15.0 million in Q2 2025. Cash, cash equivalents, and investments totaled $129.2 million as of June 30, 2026. The company has not generated material revenue historically and remains a development-stage enterprise.

Strategy

Management is prioritizing proteoform applications over broadscale analysis, reallocating resources rather than increasing spend. The new roadmap targets Early Access for AKT1 in late 2026 and consumable kit availability for Tau and AKT1 in mid-2027, with additional oncology proteoform assays planned. The company made its first sales hires in Q2 2026, building toward commercial launch. Voyager platform pre-orders are expected in early 2027, with instrument shipment anticipated in mid-2027. The broadscale consumable kit timeline has been delayed indefinitely pending further development.

Risks

• Development stage and no profitability — Nautilus has incurred net losses in every period since inception and expects to continue losing money; it may never achieve profitability.
• Platform commercialization delays — The Nautilus Voyager platform is still under development and may face technical challenges, delays, or market acceptance issues that jeopardize commercial viability.
• Broadscale assay setback — The company halted 2027 general availability for its broadscale consumable kit after failing to meet target specifications, and has not provided a new commercial timeline.
• Dependence on third parties and manufacturing — Nautilus relies on third parties for manufacturing and supplies, and the complex production of instruments and reagents may encounter unexpected difficulties.

Outlook

Management expects to launch the Voyager platform with pre-orders in early 2027 and instrument shipments beginning mid-2027, aligned with consumable kit availability. Proteoform assays for Tau and AKT1 are slated for general availability in mid-2027, with a second oncology proteoform assay also expected then. The company plans to report on a commercial timeline for the broadscale assay at a future date, and expects the reallocation to not impact broader financial assumptions.